Works in Cancer Chemotherapy & Pharmacology, 2021, Vol 87, Issue 5

Results: 15

Detecting DPD deficiency: when perfect is the enemy of good.

Published in:

2021

By:

Ciccolini, Joseph;
Milano, Gérard;
Guchelaar, Henk-Jan

Publication type:

Letter

Anticancer potential of metformin: focusing on gastrointestinal cancers.

Published in:

2021

By:

Khezri, Mohammad rafi;
Melekinejad, Hassan;
Majidi-Zolbanin, Naime;
Ghasemnejad-Berenji, Morteza;
Malekinejad, Hassan

Publication type:

journal article

Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 681, doi. 10.1007/s00280-021-04247-9

By:

Liu, Duo;
Li, Xuehua;
Li, Xiang;
Wang, Huiqi;
Dong, Mei

Publication type:

Article

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 673, doi. 10.1007/s00280-021-04245-x

By:

Lynce, Filipa;
Williams, James T.;
Regan, Meredith M.;
Bunnell, Craig A.;
Freedman, Rachel A.;
Tolaney, Sara M.;
Chen, Wendy Y.;
Mayer, Erica L.;
Partridge, Ann H.;
Winer, Eric P.;
Overmoyer, Beth

Publication type:

Article

Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 701, doi. 10.1007/s00280-021-04243-z

By:

Liu, Yang;
Cao, Yongde;
Xiao, Leting;
Wang, Haijiang

Publication type:

Article

Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk.

Published in:

2021

By:

Burns, Kathryn E.;
Chavani, Ottiniel;
Jeong, Soo Hee;
Duley, John A.;
Porter, David;
Findlay, Michael;
Strother, R. Matthew;
Helsby, Nuala A.

Publication type:

journal article

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 689, doi. 10.1007/s00280-021-04239-9

By:

Li, Chao;
Hart, Lowell;
Owonikoko, Taofeek K.;
Aljumaily, Raid;
Rocha Lima, Caio Max;
Conkling, Paul R.;
Webb, Roy Timothy;
Jotte, Robert M.;
Schuster, Steven;
Edenfield, William J.;
Smith, Deborah A.;
Sale, Mark;
Roberts, Patrick J.;
Malik, Rajesh K.;
Sorrentino, Jessica A.

Publication type:

Article

Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 647, doi. 10.1007/s00280-021-04238-w

By:

Yi, Xianglan;
Lou, Liping;
Wang, Jun;
Xiong, Jing;
Zhou, Sheng

Publication type:

Article

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 621, doi. 10.1007/s00280-020-04221-x

By:

Khosravan, Reza;
DuBois, Steven G.;
Janeway, Katherine;
Wang, Erjian

Publication type:

Article

Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study).

Published in:

2021

By:

Ishibashi, Keiichiro;
Aoyama, Toru;
Kotaka, Masahito;
Satake, Hironaga;
Tsuji, Yasushi;
Kataoka, Masato;
Nakamura, Masato;
Nagata, Naoki;
Sakamoto, Junichi;
Oba, Koji;
Mishima, Hideyuki

Publication type:

journal article

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 599, doi. 10.1007/s00280-020-04229-3

By:

Collier, Katharine A.;
Valencia, Hugo;
Newton, Herbert;
Hade, Erinn M.;
Sborov, Douglas W.;
Cavaliere, Robert;
Poi, Ming;
Phelps, Mitch A.;
Liva, Sophia G.;
Coss, Christopher C.;
Wang, Jiang;
Khountham, Soun;
Monk, Paul;
Shapiro, Charles L.;
Piekarz, Richard;
Hofmeister, Craig C.;
Welling, D. Bradley;
Mortazavi, Amir

Publication type:

Article

A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 613, doi. 10.1007/s00280-020-04225-7

By:

Sarkar, Sunit;
Tran, Ben;
Horvath, Lisa;
Lam, Michael;
Savas, Peter;
Grimison, Peter;
Whittle, James R.;
Kuo, James C.;
Signal, Nicole;
Edmonds, David;
Hogg, Philip;
Rischin, Danny;
Desai, Jayesh;
Hamilton, Anne

Publication type:

Article

Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 635, doi. 10.1007/s00280-020-04223-9

By:

Gao, Ling;
Lau, Yiu-Keung;
Wei, Ran;
O'Brien, Lisa;
Long, Amanda;
Piao, Yongzhe;
Abada, Paolo

Publication type:

Article

Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 657, doi. 10.1007/s00280-021-04236-y

By:

Saarenheimo, Jatta;
Wahid, Nesna;
Eigeliene, Natalja;
Ravi, Ravichandra;
Salomons, Gajja S.;
Ojeda, Matilde Fernandez;
Vijzelaar, Raymon;
Jekunen, Antti;
van Kuilenburg, André B. P.

Publication type:

Article

Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level.

Published in:

Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 5, p. 721, doi. 10.1007/s00280-020-04166-1

By:

Gong, Anjing;
Ge, Na;
Yao, Weicheng;
Lu, Luxiang;
Liang, Hui

Publication type:

Article